# US 7,745,637 B2 · Peptide deformylase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,637 B2
- Document ID: US7745637B2
- Status: Granted
- Kind: B2
- Application number: 11/675,788
- Filed: 2007-02-16
- Published: 2007-07-05
- Granted: 2010-06-29
- Earliest claimed: 2007-02-16
- Assignees: GlaxoSmithKline LLC
- Inventors: Kelly M. Aubart; Ajita Bhat; Sigfried B. Christensen, IV; Jack D. Leber; Xiangmin Liao
- Web page: https://patentgrep.com/patent/US7745637B2

## CPC

- C07D 233/76: with substituted hydrocarbon radicals attached to the third ring carbon atom
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- C07D 233/78: Radicals substituted by oxygen atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel PDF inhibitors and novel methods for their use are provided.

## Claims

### Claim 1

A compound according to Formula (I):
wherein
R1 is selected from the group consisting of C1-C9alkyl, C1-2alkylAr, and Ar;
R2 is selected from the group consisting of hydrogen, C1-C9alkyl, C1-4alkylAr′, NHR4, NHC(O)R4, C2-4alkylNR3R4, C1-3alkylC(O)NR3R4, C1-3alkylC(O)Ar′, C2-3alkylNHC(O)NR3R4, C2-3alkylNHC(O)Ar′, and C1-2alkylSO2R4;
R3 is selected from the group consisting of C1-C9alkyl, C1-2alkylAr, and Ar;
R4 is R3, Ar′, or R4 may be taken together with R3 and the nitrogen atom to which they are attached to form a heterocyclic ring which is optionally substituted with one, two, or three substituents each independently selected from the group consisting of C1-3alkyl, aryl, C1-3alkoxy (optionally substituted by one to three F), aryloxy, carboxy, oxo, hydroxy, amino, nitro, and cyano, or which may be optionally fused to an aryl, a heteroaryl, or a second heterocyclic ring;
Ar is selected from the group consisting of phenyl, furyl, and thienyl, all of which can be optionally substituted with one, two, or three substituents each independently selected from the group consisting of: C1-C3alkyl, CN, F, Cl, Br, and I; and
Ar′ is selected from the group consisting of: naphthyl, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, benzofuranyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, and pyrimidyl, all of which can be optionally substituted with one, two, or three substituents each independently selected from the group consisting of: C1-C6alkyl, C1-C6alkoxy, (CH2)0-5CO2R1, C(O)N(R1)2, CN, (CH2)0-5OH, NO2, F, Cl, Br, I, CF3, N(R1)2, and NHC(O)R1; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 3

A compound selected from the group consisting of:
N-[(S)-2,5-Dioxo-4-pentyl-1-phenyl-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
N-[(S)-1-Biphenyl-4-ylmethyl-4-butyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;
N-{(S)-4-Butyl-1-[2-(5-chloro-3-methyl-1-benzo[b]thiophen-2-yl)-2-oxo-ethyl]-2,5-dioxo-imidazolidin-4-ylmethyl}-N-hydroxyformamide; and
2-{(S)-4-Butyl-4-[(formyl-hydroxy-amino)methyl]-2,5-dioxo- imidazolidin-1-yl}-N-(3,5-dichlorophenyl)acetamide;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

A pharmaceutical composition comprising a compound according to claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.